Literature DB >> 26605428

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.

Ryan A Denu1, John M Hampton2, Adam Currey3, Roger T Anderson4, Rosemary D Cress5, Steven T Fleming6, Joseph Lipscomb7, Susan A Sabatino8, Xiao-Cheng Wu9, J Frank Wilson3, Amy Trentham-Dietz10.   

Abstract

PURPOSE: Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer for which treatments vary, so we sought to identify factors that affect the receipt of guideline-concordant care.
METHODS: Patients diagnosed with IBC in 2004 were identified from the Breast and Prostate Cancer Data Quality and Patterns of Care Study, containing information from cancer registries in seven states. Variation in guideline-concordant care for IBC, based on National Comprehensive Cancer Network (NCCN) guidelines, was assessed according to patient, physician, and hospital characteristics.
RESULTS: Of the 107 IBC patients in the study without distant metastasis at the time of diagnosis, only 25.8% received treatment concordant with guidelines. Predictors of non-concordance included patient age (≥70 years), non-white race, normal body mass index (BMI 18.5-25 kg/m(2)), patients with physicians graduating from medical school >15 years prior, and smaller hospital size (<200 beds). IBC patients survived longer if they received guideline-concordant treatment based on either 2003 (p=0.06) or 2013 (p=0.06) NCCN guidelines.
CONCLUSIONS: Targeting factors associated with receipt of care that is not guideline-concordant may reduce survival disparities in IBC patients. Prompt referral for neoadjuvant chemotherapy and post-operative radiation therapy is also crucial.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Epidemiology; Guideline; Healthcare disparities; Inflammatory breast cancer

Mesh:

Year:  2015        PMID: 26605428      PMCID: PMC4738104          DOI: 10.1016/j.canep.2015.11.003

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  39 in total

1.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.

Authors:  N T Ueno; A U Buzdar; S E Singletary; F C Ames; M D McNeese; F A Holmes; R L Theriault; E A Strom; B J Wasaff; L Asmar; D Frye; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

2.  Does Center Volume Correlate with Survival from Breast Cancer?

Authors:  Anton Scharl; Uwe-Jochen Göhring
Journal:  Breast Care (Basel)       Date:  2009-08-12       Impact factor: 2.860

Review 3.  Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.

Authors:  B E Hillner; T J Smith; C E Desch
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  Inflammatory carcinoma of the breast. A pathologic definition.

Authors:  D L Ellis; S L Teitelbaum
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

5.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Authors:  S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

6.  Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

Authors:  Tamer M Fouad; Takahiro Kogawa; Diane D Liu; Yu Shen; Hiroko Masuda; Randa El-Zein; Wendy A Woodward; Mariana Chavez-MacGregor; Ricardo H Alvarez; Banu Arun; Anthony Lucci; Savitri Krishnamurthy; Gildy Babiera; Thomas A Buchholz; Vicente Valero; Naoto T Ueno
Journal:  Breast Cancer Res Treat       Date:  2015-05-29       Impact factor: 4.872

7.  Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust.

Authors:  Nina A Bickell; Jessica Weidmann; Kezhen Fei; Jenny J Lin; Howard Leventhal
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

8.  Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy.

Authors:  R Zucali; C Uslenghi; R Kenda; G Bonadonna
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

9.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.

Authors:  Ian J Bristol; Wendy A Woodward; Eric A Strom; Massimo Cristofanilli; Delora Domain; S Eva Singletary; George H Perkins; Julia L Oh; Tse-Kuan Yu; Welela Terrefe; Aysegul A Sahin; Kelly K Hunt; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-24       Impact factor: 7.038

10.  Comorbidity burden and guideline-concordant care for breast cancer.

Authors:  Gretchen Kimmick; Steven T Fleming; Susan A Sabatino; Xiao-Cheng Wu; Wenke Hwang; J Frank Wilson; Mary Jo Lund; Rosemary Cress; Roger T Anderson
Journal:  J Am Geriatr Soc       Date:  2014-02-10       Impact factor: 5.562

View more
  5 in total

1.  Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care.

Authors:  George Simon; Courtney D DiNardo; Koichi Takahashi; Tina Cascone; Cynthia Powers; Rick Stevens; Joshua Allen; Mara B Antonoff; Daniel Gomez; Pat Keane; Fernando Suarez Saiz; Quynh Nguyen; Emily Roarty; Sherry Pierce; Jianjun Zhang; Emily Hardeman Barnhill; Kate Lakhani; Kenna Shaw; Brett Smith; Stephen Swisher; Rob High; P Andrew Futreal; John Heymach; Lynda Chin
Journal:  Oncologist       Date:  2018-11-16

2.  Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer.

Authors:  Courtney P Williams; Kelly M Kenzik; Andres Azuero; Grant R Williams; Maria Pisu; Karina I Halilova; Stacey A Ingram; Supriya K Yagnik; Andres Forero; Smita Bhatia; Gabrielle B Rocque
Journal:  Oncologist       Date:  2018-08-17

3.  Guideline-Consistent Treatment for Inflammatory Breast Cancer Provides Associated Survival Benefit Independent of Age.

Authors:  Lauren M Drapalik; Jonathan J Hue; Ashley Simpson; Mary Freyvogel; Lisa Rock; Robert R Shenk; Amanda L Amin; Megan E Miller
Journal:  Ann Surg Oncol       Date:  2022-08-08       Impact factor: 4.339

4.  A meta-analysis of Watson for Oncology in clinical application.

Authors:  Zhou Jie; Zeng Zhiying; Li Li
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

Review 5.  Progress of Artificial Intelligence in Gynecological Malignant Tumors.

Authors:  Jie Zhou; Zhi Ying Zeng; Li Li
Journal:  Cancer Manag Res       Date:  2020-12-14       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.